Shuttle Pharmaceuticals Holdings, Inc.
Business
Shuttle Pharmaceuticals Holdings is a pharmaceutical company that acquired Molecule.ai, an AI-driven platform for molecular discovery and early-stage drug development. The platform uses transformer-based models and large language models to predict molecular properties, evaluate cross-molecule trade-offs, and provide structured scientific reasoning for researchers. The company operates in pharmaceutical research and development, serving discovery teams through cloud-accessible software tools. The company has wound down clinical trials of its prior lead candidate and is repositioning toward AI-enabled drug discovery infrastructure.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | |
| Research and development | 4 | 4 | 4 | 1 | 1 | |
| General and administrative | 6 | 1 | 1 | 538,796 | 36,500 | |
| Legal and professional | 2 | 3 | 1 | 866,770 | 684,684 | |
| Total operating expenses | 12 | 8 | 6 | 3 | 2 | |
| Net loss from operations | −12 | −8 | −6 | −3 | −2 | |
| Interest income | 1,090 | 38,138 | 79,117 | — | — | |
| Convertible notes finance fee | — | −152,726 | −104,245 | — | — | |
| Change in fair value of derivative liabilities | −74,406 | 555,789 | 2 | 94,025 | — | |
| Change in fair value of convertible notes | −3,351 | 122,553 | — | — | — | |
| Gain on sale of marketable securities | — | 28,550 | 4,970 | — | — | |
| Gain on settlement of debt | 342,650 | — | — | 328,687 | — | |
| Loss on settlement of convertible debt | — | −833,501 | −477,221 | — | — | |
| Total other (expense) income | 195,155 | −1 | −700,341 | −474,170 | 590,858 | |
| Net loss | −12 | −9 | −7 | −3 | −1 | |
| Weighted average common shares outstanding - basic | 2 | 114,807 | 2 | 10 | 9 | |
| Net loss per shares - basic | −7.16 | −79.65 | −3.53 | −0.29 | −0.12 | |
| Weighted average common shares outstanding - diluted | 2 | 115,493 | 2 | 10 | — | |
| Net loss per share - diluted | −7.16 | −82.6 | −3.53 | −0.29 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 334,005 | 2 | 3 | 8 | 504,749 | |
| Prepaid expenses and other current assets | 168,906 | 290,773 | — | — | — | |
| Total current assets | 502,911 | 2 | 6 | 9 | 509,615 | |
| Property and equipment, net | 17,319 | 19,364 | 24,827 | 12,592 | 18,564 | |
| Intangible assets, net | 10 | — | — | — | — | |
| Deferred financing costs | 12,122 | — | — | — | — | |
| Operating lease right-of-use asset | 102,383 | 276,009 | 333,904 | 56,122 | 116,982 | |
| Total Assets | 10 | 3 | 6 | 9 | 651,641 | |
| Accounts payable and accrued expenses | 1 | 596,600 | — | — | — | |
| Contingent consideration liability | 2 | — | — | — | — | |
| Consideration payable | 4 | — | — | — | — | |
| Accrued interest payable - related parties | — | 1,785 | — | — | — | |
| Notes payable to related parties | — | 190,270 | — | — | — | |
| Operating lease liability | 77,194 | 60,909 | 52,479 | 62,823 | 66,934 | |
| Total current liabilities | 8 | 2 | 1 | 975,676 | 2 | |
| Derivative liability | 99,687 | 25,281 | 414,512 | — | — | |
| Operating lease liability non-current | 154,953 | 238,088 | 304,127 | — | 62,442 | |
| Total Liabilities | 8 | 2 | 2 | 975,676 | 2 | |
| Commitments and contingencies (Note 9) | — | — | — | — | — | |
| Series A Convertible Preferred Stock, $0.00001 par value; $1,000 per share liquidation value; 20,000,000 shares authorized; no shares outstanding | — | — | — | — | — | |
| Common stock, $0.00001 par value; 100,000,000 shares authorized; 2,023,615 shares issued and outstanding at December 31, 2025; 163,093 shares issued and outstanding at December 31, 2024 | 20 | 2 | 20 | 136 | 93 | |
| Additional paid in capital | 49 | 35 | 29 | 17 | — | |
| Accumulated deficit | −46 | −35 | −25 | −9 | −6 | |
| Total Stockholders Equity | 2 | 709,152 | 4 | 8 | −2 | |
| Total Liabilities and Stockholders Equity | 10 | 3 | 6 | 9 | 651,641 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 290,107 | 5,463 | — | — | — | |
| Amortization of debt discount and finance fees | 62,030 | 1 | 2 | 885,505 | 3,389 | |
| Gain on settlement of debt | 342,650 | — | — | — | — | |
| Accrued interest settled with common stock | — | 54,670 | 294,927 | — | — | |
| Stock-based compensation | 932,967 | 259,744 | 181,960 | 403,956 | 910,067 | |
| Expense for debt issuance costs due to fair value election on convertible notes | — | 107,491 | — | — | — | |
| Expense for issuance costs due to liability classified warrants | — | 28,477 | — | — | — | |
| Loss on issuance of convertible notes - fair value option | — | 16,758 | — | — | — | |
| Impairment of right-of-use asset | 109,235 | — | — | — | — | |
| Interest payments on convertible notes accounted for at fair value | −115,339 | — | — | — | — | |
| Accrued interest income | — | 14,901 | −14,901 | — | — | |
| Prepaid expenses | 121,867 | −176,300 | 46,675 | −156,282 | 7,713 | |
| Accounts payable and accrued expenses | 422,994 | 313,741 | 166,115 | −382,881 | — | |
| Accounts payable and accrued expenses - related parties | — | −446 | −12,054 | 12,500 | — | |
| Accrued interest payable | — | −15,056 | 110,453 | −13,177 | 160 | |
| Accrued interest payable - related parties | −1,785 | 1,785 | −98,135 | 51,188 | — | |
| Other assets | — | — | 6,480 | — | — | |
| Change in operating lease asset and liabilities | −2,459 | 286 | 16,001 | −5,693 | −58,468 | |
| Net cash used in operating activities | −9 | −7 | −6 | −3 | −300,336 | |
| Investment in marketable securities | — | −43,587 | −3 | — | — | |
| Proceeds from disposition of marketable securities | — | 3 | 187,895 | — | — | |
| Payments made for capitalized software | −12,000 | — | — | — | — | |
| Investment in developed technology related to Molecule.ai Asset Acquisition | −3 | — | — | — | — | |
| Net cash (used in) provided by investing activities | −3 | 3 | −3 | — | — | |
| Proceeds from note payable-related party | — | 250,000 | — | 50,000 | 120,000 | |
| Repayment of note payable-related party | −190,270 | −59,730 | −685,473 | −50,000 | — | |
| Proceeds from convertible notes payable | — | 790,000 | 4 | 600,715 | — | |
| Proceeds from issuance of common stock, warrants and pre-funded warrants, net of placement agent fees of $504,770 | — | 4 | — | 10 | — | |
| Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs of $322,501 | 5 | — | — | — | — | |
| Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs of $170,000 | 4 | — | — | — | — | |
| Proceeds from issuance of pre-funded warrants, net of issuance costs of $235,514 | 2 | — | — | — | — | |
| Payment of other issuance costs for issuance of common stock and equity-classified warrants | −557,659 | −235,707 | — | — | — | |
| Payment for issuance costs related to liability-classified warrants | — | −28,477 | — | — | — | |
| Proceeds from exercise of pre-funded warrants | 20,151 | 729 | — | — | — | |
| Payment for finance costs | −74,152 | −107,491 | −345,000 | — | — | |
| Payment of convertible note payable | — | −846,806 | — | — | — | |
| Net cash provided by (used in) financing activities | 11 | 4 | 3 | 11 | 687,932 | |
| Net change in cash and cash equivalents | −2 | −656,272 | −6 | 8 | 387,596 | |
| Interest | 125,296 | 86,589 | 164,807 | 39,201 | 293 | |
| Income taxes | — | — | — | — | — | |
| Conversion of convertible notes accounted for at at fair value | 572,217 | — | — | — | — | |
| Issuance costs in accrued expenses | 18,944 | — | — | — | — | |
| Asset acquisition costs in accounts payable and accrued expenses | 72,582 | — | — | — | — | |
| Common stock issued for settlement of debt | — | 2 | 3 | 588,524 | — | |
| Common stock issued for Molecule.ai Asset Acquisition | 564,073 | — | — | — | — | |
| Consideration payable recognized in asset acquisition | 4 | — | — | — | — | |
| Contingent consideration recognized in asset acquisition | 2 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Shuttle Pharmaceuticals Holdings, Inc.'s CIK number?
Shuttle Pharmaceuticals Holdings, Inc.'s SEC CIK number is 0001757499 (1757499). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Shuttle Pharmaceuticals Holdings, Inc.'s SEC filings?
All of Shuttle Pharmaceuticals Holdings, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Shuttle Pharmaceuticals Holdings, Inc. last report earnings?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) most recently filed an earnings 8-K with the SEC on Feb 17, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-007204). This is Shuttle Pharmaceuticals Holdings, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Shuttle Pharmaceuticals Holdings, Inc.'s most recent earnings 8-K?
Shuttle Pharmaceuticals Holdings, Inc.'s latest earnings 8-K (Item 2.02) was filed Feb 17, 2026 under accession 0001493152-26-007204. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Shuttle Pharmaceuticals Holdings, Inc.'s latest earnings 8-K →
Look up any company's CIK number →